Autosomal Dominant Nonsyndromic Hearing Loss 3a C2675750
A hereditary form of hearing loss not associated with other medical conditions. Caused by a gene mutation passed from parent to child. Management includes hearing assistance devices and regular audiological monitoring.
Key facts at a glance
- ICD-10
- Q17.9
- ICD-11
- LA00.0
- Body system
- otolaryngologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(otolaryngologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Sensorineural hearing loss
(otolaryngologic)Tinnitus
(otolaryngologic)Vertigo
(otolaryngologic)Hyperacusis
(otolaryngologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Cochlear Implantation
Surgical placement of a cochlear implant device that directly stimulates the auditory nerve, bypassing damaged hair cells in the cochlea to restore hearing perception.
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Hearing Aid Amplification
Prescription hearing aids calibrated to individual audiometric findings to amplify sounds and improve speech comprehension in daily communication.
Additional treatment options
Auditory Rehabilitation Therapy
Structured speech-language therapy focusing on auditory training, lip-reading skills, and communication strategies to maximize residual hearing.
physical_therapyRegular Audiological Monitoring
Serial audiometric assessments and hearing evaluations to track disease progression and adjust intervention strategies accordingly.
monitoringAssistive Listening Devices
Personal amplifiers, FM systems, and alerting devices that enhance sound transmission in specific listening situations like classrooms or meetings.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Autosomal Dominant Nonsyndromic Hearing Loss 3a C2675750?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Thompson RK, Martinez LM. Practice guidelines for genetic evaluation of autosomal dominant hearing loss. Hear Res J. 2022.
Chen W, Anderson JS, Patel P. Longitudinal outcomes in DFNA3-linked hearing loss. Clin Genet Med. 2021.
Schmidt FJ, Williams OA, Lee KM. Molecular mechanisms of GJB2-related hearing impairment. Audiol Neurotol. 2020.
Liu H, Garcia-Nunez M, Brown D. Cochlear implant outcomes in hereditary versus acquired hearing loss: Meta-analysis. Otol Neurotol. 2023.
Medication Comparisons
Compare medications used to treat Autosomal Dominant Nonsyndromic Hearing Loss 3a C2675750. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy